Prognostic Role of Tumor-Infiltrating Lymphocytes and Tumor Budding in Early Oral Tongue Carcinoma

Yukiko Hori, MD; Akira Kubota, MD, PhD; Tomoyuki Yokose, MD, PhD; Madoka Furukawa, MD, PhD; Takeshi Matsushita, MD; Noriyuki Katsumata, MD; Nobuhiko Oridate, MD, PhD

**Objectives/Hypothesis:** Occult lymph metastasis is an important prognosticator for the treatment of early oral tongue squamous cell carcinoma (SCC). The objective of this study was to evaluate the prognostic significance of tumor-infiltrating lymphocytes (TILs) in early oral tongue SCC. The combination of the TIL subtype and intermediate- or high-grade budding scores was investigated as a prognostic marker for occult neck metastases.

**Study Design:** Retrospective study.

**Methods:** Specimens from 62 patients with early oral tongue SCC treated with only primary surgery were analyzed by immunohistochemistry for CD4+, CD8+, FoxP3+, and CD45RO+ T cells and CD163+ macrophages. The highest number of each TIL subtype was counted in two areas of parenchyma and stroma in the tumor (Tumor) and peripheral stroma of the invasion margin.

**Results:** Based on multivariate analysis, a high density of Tumor CD163+ macrophages served as the poorest prognostic factor for regional control (RC) and disease-free survival (DFS). Patients with both a high density of Tumor CD163+ macrophages and an intermediate- or a high-grade budding score had a poor prognosis for RC according to the log-rank test.

**Conclusions:** In summary, each TIL subtype may use different mechanisms during early and advanced stages of oral tongue SCC. A high density of Tumor CD163+ macrophages was determined to be a risk factor for RC and DFS as well as an additional stratification factor for RC in patients with intermediate- or high-grade budding scores. Therefore, identifying TIL subtypes in daily clinical practice can help determine a more successful and individualized therapeutic approach for early oral tongue SCC.

**Key Words:** Head and neck cancer, early oral tongue carcinoma, tumor-infiltrating lymphocytes, CD163+ macrophage, tumor budding.

**Level of Evidence:** Step 4 (Level 4)

Laryngoscope, 00:1–7, 2021

INTRODUCTION

Management of the diagnosis and treatment of early oral tongue squamous cell carcinoma (SCC) is controversial. Depth of invasion (DOI) has been added to the T classification in the eighth edition of the American Joint Commission on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification. These changes were made because occult lymph node metastases are reported in 20% to 40% of early oral tongue SCC, which are major prognostic factors of the disease.1–6

Tumor budding (TB) is defined as the invasion of a single cell or small clusters of tumor cells (<5 cells) at the tumor invasive front.7 According to the scoring system of the International Tumor Budding Consensus Conference, the budding score is defined as the highest amount of TB viewed at 20×, and a score <5 is defined as low grade, <10 as intermediate grade, and ≥10 as high grade.8 Previously, we found few late neck metastases in patients with low-grade budding score in early oral tongue SCC. Moreover, the BD model, which is a combination of TB and DOI, has been shown as a useful pathological prognostic factor for lymph node metastases.9–10 Recent studies reported the prognostic significance of TB for oral SCC (OSCC).11–15

The recent elucidation of the mechanisms of the tumor microenvironment in tumor progression led to remarkable breakthrough in the field of cancer immunotherapy. Determination of immune mechanisms and identification of novel prognostic biomarkers are useful for selecting the best cancer therapy to improve survival rates.16

In the current study, we focused on inflammatory cells in the early stages of oral tongue SCC, which are thought to define the states before and after microscopic metastasis. It has been reported that combinations of pathological...
characteristics such as tumor invasion patterns, TB and DOI, and immune cells are useful predictors of occult neck metastases.\textsuperscript{17–18} Thus, we investigated tumor-infiltrating lymphocytes (TILs) as an additional stratification factor that may be associated with occult neck metastases in patients with intermediate- or high-grade budding scores.

**MATERIALS AND METHODS**

**Patients**

Examination by computed tomography (CT), magnetic resonance imaging, ultrasonography, and positron emission tomography/CT (since 2004) was performed prior to surgery. All patients underwent excision of the primary tumor with adequate margins (≥10 mm). Patients were followed by examination with ultrasonography or CT once every 1 to 3 months for the first 2 years. For neck recurrence, selected neck dissection (ND) was performed. Postoperative radiotherapy or concurrent chemoradiotherapy was recommended for cases with adverse features.\textsuperscript{9–10} A total of 189 patients were diagnosed with clinical early oral tongue SCC between September 2000 and March 2017 at the Kanagawa Cancer Center. Excluding patients with carcinoma in situ, recurrence of SCC, history of preoperative chemotherapy, or high-dose-rate brachytherapy, 62 patients were enrolled in the current study.

The staging was classified according to the eighth edition of the AJCC/UICC TNM classification. The study was approved by the Ethics Committee of Kanagawa Cancer Center. Informed consent was obtained from all individual participants included in the study. The procedures complied with the Declaration of Helsinki.

**Immunohistochemical Staining**

Resected tissues 4-μm thickness were fixed with 10% buffered formalin and embedded in paraffin. The paraffin-embedded sections were incubated with antibodies for pan-cytokeratin (clone AE1/AE3/PCK26, Ventana Medical Systems, Tucson, AZ; ready to use), CD4 (clone SP35, Ventana Medical Systems; ready to use), CD8 (clone SP57, Ventana Medical Systems; ready to use), forkhead box P3\textsuperscript{+} (FoxP3, clone 236A/E7, Nichirei, Tokyo, Japan; 1:200), CD163 (clone 10D6, Nichirei, Tokyo, Japan; 1:200), CD45RO (clone AE1/AE3/PCK26, Ventana Medical Systems, Tucson, AZ; ready to use), forkhead box P3\textsuperscript{+} (FoxP3, clone 236A/E7, Nichirei, Tokyo, Japan; 1:200), CD163 (clone 10D6, Nichirei; 1:100), and CD45RO (clone UCHL1, Nichirei; ready to use) (Fig. 1).

Immunohistochemistry analysis of pan-cytokeratin, CD4, and CD8 was performed using the BenchMark ULTRA instrument (Ventana Medical Systems). Immunohistochemistry analysis of FoxP3\textsuperscript{+}, CD163, and CD45RO was performed as follows. The tissue sections were deparaffinized in xylene, rehydrated with an alcohol gradient, and rinsed with a phosphate buffer solution (washing buffer; pH 9.0; Nichirei). The sections were quenched with peroxidase-blocking solution (Dako, Carpinteria, CA; ready to use) for 5 min, washed with the washing buffer, and incubated for 30 min with primary antibodies against FoxP3, CD163, and CD45RO. After rinsing with washing buffer, the sections were incubated for 30 min with the secondary antibody clone UCHL1 (Nichirei; ready to use) and washed again. The sections were immersed in a solution of 3,3’-diaminobenzidine (Dako) for visualization and counterstained with hematoxylin.

**Evaluation of Staining**

Histopathological review was performed by one of the authors and an experienced pathologist blinded to the patients’ conditions (Y.H. and T.Y., respectively). In addition, the labels of the pathology specimens were de-identified. TB was assessed using pan-cytokeratin-immunostained sections. The number of immune cells was counted with a computerized image analysis system, Patholoscope ver.1.2.1 (Mitani Corporation, Fukui, Japan). Immune cells were identified by their specific markers, including CD4, CD8, FoxP3, CD163, and CD45RO. The software can recognize and count positive and negative cells separately in immunostaining image formats using a technical cell extraction algorithm. The count of immune cells was normalized with a semiautosystem of Patholoscope. For each marker, a maximum of one view (0.843 × 0.634 mm per one format) was examined at 20×. Two areas of parenchyma and stroma in the tumor (Tumor) and peripheral stroma at outside of the tumor invasion margin (Stroma) in which the highest number of each TIL subtype was found were selected to evaluate the staining (Fig. 2).

**Statistical Analysis**

All statistical analyses were performed using SPSS version 23.0 (IBM Corp, Armonk, NY). Regional control (RC) was defined as the period between the primary surgery and regional recurrence. Disease-free survival (DFS) was defined as the period between the primary surgery and first recurrence, last examination, or death due to any cause. The prognostic factors for lymph node metastases and DFS were analyzed by the Kaplan–Meier method and univariate analysis with log-rank tests using clinical characteristics (sex, pathological T stage, differentiation, budding score, and DOI) and each subtype of immune cells in the Tumor and Stroma. The median number of each immune cell subtype was used as the cutoff value to divide the samples into low- and high-infiltrating groups. A Cox proportional hazards model was used to test the risk factors of clinical characteristics and poorest prognostic subtype of immune cells detected by univariate analysis. Correlations for each factor were analyzed using Spearman’s rank correlation coefficient. \( P \)-values <.05 were considered significant.

The subtypes of immune cells that showed significance in the multivariate analysis and budding score were evaluated. Combined evaluation was performed by categorizing the subtypes into three groups; group 1: low-density subtype and low-grade budding score, group 2: high-density subtype or intermediate/high-grade budding score, and group 3: high-density subtype and intermediate/high-grade budding score. The associations between each group and the DOI were evaluated using the Mann–Whitney U test.

**RESULTS**

Forty-three (69%) of the 62 patients were men and 19 were women, with a median age of 61 years (range, 31–87 years). The median follow-up duration was 68 months (range, 8–201 months). Thirty-five (56%) and 27 (44%) patients were classified as having stage I and II diseases, respectively (Table I). Eleven patients had tumors with DOI >5 mm. Neck recurrence was observed in 15 patients within 2 years after the primary surgery. Excluding one patient treated with definitive chemoradiotherapy, selective ND was performed in 14 patients (93%). Pathological N1, 2, and 3b recurrence was observed in 4 (29%), 4 (29%), and 6 (43%) patients, respectively. Three, eight, four, two, and one recurrence were localized from level I to V of the ipsilateral side, respectively. Finally, 10 patients were salvaged.

Eight (13%) and two (3%) patients succumbed to the original disease and other causes, respectively. The 5-year RC and DFS rates were 74% and 65%, respectively. Based on univariate analysis, prognostic factors for both
RC and DFS were identified as intermediate- or high-grade budding score ($P < .01$ for both) and DOI >5 mm ($P < .05$ and $P < .01$, respectively) (Table I).

The median numbers of Tumor and Stroma CD4+ T cells were 532 (4–3,727 cells) and 838 (128–3,059 cells), respectively; Tumor and Stroma CD8+ T cells were 370

Fig. 1. Representative photomicrographs of tumor-infiltrating lymphocytes in oral squamous cell carcinoma ($\times 20$). The immunohistochemistry staining of CD4 (A, B), CD8 (C, D), FoxP3 (E, F), CD163 (G, H), CD45RO (I, J), and pan-cytokeratin (K, L) was performed. (A, C, E, G, and I) High density of each tumor-infiltrating lymphocyte subtype at Stroma of nearly same areas. (B, D, F, H, and J) Low density in other patients. The budding score was counted as the largest number of TB viewed at $\times 20$. K and L show high- and low-grade budding scores, respectively.

Fig. 2. Computerized image analysis system, Patholoscope was used to count the number of immune cells. The pictures of the immunohistochemistry staining of CD163+ macrophage were shown. Immune cells were counted in two areas of parenchyma and stroma in the tumor (Tumor) and peripheral stroma that was outside of the tumor invasion margin (Stroma) at a maximum of one view (0.843 x 0.634 mm) at $\times 20$ (A). From the immunostaining image format (B, D), the software extracted positive cells (small yellow circles) and negative cells (small purple circles) and counted them automatically (C, E). High density of CD+ macrophages at both of Stroma and Tumor areas were shown.
CD45RO Tumor CD4 factors for DFS (Table II). Multivariate analysis identified independent risk factors for RC. Furthermore, a high density of Tumor CD163+ macrophages (HR, 2.11; 95% CI, 0.75–5.94; P < .05) and an intermediate or a high grade of budding score (HR, 17.91; 95% CI, 2.28–114.46; P < .01) as risk factors for RC. Additionally, high densities of Tumor FoxP3+ cells, Tregs, and TAMs have been reported by many studies.29 Tregs are a small subset of CD4+ T cells and suppress the activation and proliferation of immune cells.28 FoxP3 is a transcription factor and specific marker of Tregs.29 TAMs are macrophages present in the tumor microenvironment. Upon stimulation, TAMs are polarized into one of two main types: M1 macrophages, which have proinflammatory and antitumor roles, and M2 macrophages, which have immunosuppressive and tumor-promoting roles.19 CD163 is a specific marker of M2 macrophages.29 CD45RO+ memory T cells are maintained for years in the body after encountering antigens; thus, CD45RO+ cells can respond to antigen re-exposure faster than after the first exposure.30

### DISCUSSION

CD4+ T cells, CD8+ T cells, Tregs, tumor-associated macrophages (TAMs), and CD45RO+ memory T cells have been assessed as prognostic markers of malignant tumors in previous studies.19–24 Particularly, CD8+ T cells, Tregs, and TAMs have been reported by many studies as key markers of the progression of a variety of cancers.25–29 Tregs are a small subset of CD4+ T cells and suppress the activation and proliferation of immune cells.28 FoxP3 is a transcription factor and specific marker of Tregs.29 TAMs are macrophages present in the tumor microenvironment. Upon stimulation, TAMs are polarized into one of two main types: M1 macrophages, which have proinflammatory and antitumor roles, and M2 macrophages, which have immunosuppressive and tumor-promoting roles.19 CD163 is a specific marker of M2 macrophages.29 CD45RO+ memory T cells are maintained for years in the body after encountering antigens; thus, CD45RO+ cells can respond to antigen re-exposure faster than after the first exposure.30

| Characteristics | RC | DFS |
|-----------------|----|-----|
| Number of Cases (%) | 75 | 62 |
| Median Survival (Mo) | 3.48 | 1.24–9.82 |
| 5-Yr RC (%) | .011 | .011 |
| HR | 16 (31) | 16 (31) |
| 95% CI | 5.94 | .005 |
| P-Value | 1.81 | .138 |
| Number of Cases (%) | 75 | 62 |
| Median Survival (Mo) | 3.48 | 1.24–9.82 |
| 5-Yr DFS (%) | .011 | .011 |
| HR | 16 (31) | 16 (31) |
| 95% CI | 5.94 | .005 |
| P-Value | 1.81 | .138 |

CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N/A = not applicable; RC = regional control.
In the current study, high infiltration of Tumor CD163+ macrophages was the poorest prognostic marker for RC and DFS among all subtypes of TILs. Systematic reviews of macrophages and the prognosis of OSCC reported that an increased number of TAMs or CD163+ macrophages is a poor prognostic factor.\textsuperscript{19,29} M2 macrophages may be novel prognostic markers of RC in the early stages, and consistently through advanced stages. Most studies reported that a high density of CD8+ T cells in OSCC and head and neck SCC (HNSCC) predicts a favorable prognosis.\textsuperscript{20–22,31–33} However, univariate analysis revealed infiltration of CD8+ T cells as a risk factor for RC in the current study. The immune activity of CD8+ T cells may be promoted depending on tumor progression in the early stages; the present study simply reflected the promoted activity of CD8+ T cells based on the tumor progression for lymph node metastasis, and the activity of CD8+ T cells had a limited influence on prognosis in the early stages. Watanabe et al also reported that CD8+ T cells are significant only in the advanced as opposed to early stages in 87 patients with OSCC.\textsuperscript{34} Some studies reported that a high density of CD4+ T cells is associated with tumor progression; thus, it is a poor prognostic marker.\textsuperscript{21,35} However, increasing infiltration of FoxP3+ T cells tended to associate with poor tumor progression, which was consistent with the result

### TABLE II.
Survival Times and the Risk Factors of Inflammatory Cells for Lymph Node Recurrence and Disease Recurrence by Univariate Analysis.

| Subtype of TILs | Number of Immune Cells | Number of Cases (%) | Median Survival (Mo) | 5-Yr RC (%) | HR | 95% CI | P-Value |
|----------------|------------------------|---------------------|----------------------|-------------|----|--------|---------|
| CD4+ T cells   | Tumor                   | Low                 | 4 (13)               | 67          | 86 | 3.41   | 1.08–10.74 | .025   |
|                |                        | High                | 11 (35)              | 20          | 62 | 3.22   | 1.02–10.13 | .033   |
|                | Stroma                 | Low                 | 7 (23)               | 66          | 77 | 1.3    | 0.47–3.61  | .611   |
|                |                        | High                | 8 (26)               | 20          | 74 | 1.2    | 0.47–3.61  | .611   |
| CD8+ T cells   | Tumor                   | Low                 | 4 (13)               | 65          | 86 | 3.22   | 1.02–10.13 | .033   |
|                |                        | High                | 11 (36)              | 21          | 64 | 2.19   | 0.75–6.41  | .14    |
|                | Stroma                 | Low                 | 10 (32)              | 22          | 65 | 2.19   | 0.75–6.41  | .14    |
|                |                        | High                | 5 (16)               | 56          | 84 | 2.19   | 0.75–6.41  | .14    |
| FoxP3+ T cells | Tumor                   | Low                 | 3 (10)               | 65          | 90 | 4.66   | 1.31–16.52 | .008   |
|                |                        | High                | 12 (39)              | 22          | 59 | 8.28   | 1.86–36.84 | <.001  |
|                | Stroma                 | Low                 | 7 (23)               | 22          | 75 | 1.08   | 0.39–2.98  | .88    |
|                |                        | High                | 8 (26)               | 62          | 74 | 1.08   | 0.39–2.98  | .88    |
| CD163+ macrophages | Tumor            | Low                 | 2 (7)                | 66          | 93 | 8.28   | 1.86–36.84 | <.001  |
|                |                        | High                | 13 (42)              | 17          | 57 | 6.19   | 0.60–4.74  | .314   |
|                | Stroma                 | Low                 | 6 (19)               | 65          | 80 | 1.69   | 0.60–4.74  | .314   |
|                |                        | High                | 9 (29)               | 21          | 69 | 1.69   | 0.60–4.74  | .314   |
| CD45RO+ T cells | Tumor                   | Low                 | 4 (13)               | 66          | 87 | 3.05   | 0.95–9.43  | .047   |
|                |                        | High                | 11 (36)              | 21          | 61 | 2.18   | 0.74–6.37  | .143   |
|                | Stroma                 | Low                 | 10 (32)              | 24          | 65 | 2.18   | 0.74–6.37  | .143   |
|                |                        | High                | 5 (16)               | 58          | 84 | 2.18   | 0.74–6.37  | .143   |

CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; RC = regional control; TILs = tumor-infiltrating lymphocytes.

### TABLE III.
Multivariate Analysis of Regional Control and Disease-Free Survival by Cox Proportional Hazards Regression Model.

| Subtype of TILs | Characteristics | Hazard Ratio | 95% CI | P-Value |
|----------------|----------------|--------------|--------|---------|
| Tumor CD163+ macrophages | Tumor CD163+ macrophages | 5.06 | 1.12–22.88 | .035 |
| Budding score | 17.9 | 2.28–140.73 | .006 |
| Depth of invasion | 1.16 | 0.41–3.33 | .782 |
| Tumor CD163+ macrophages | 3.34 | 1.27–8.75 | .014 |
| Budding score | 1.95 | 0.79–4.84 | .15 |
| Depth of invasion | 1.76 | 0.65–4.73 | .263 |

CI = confidence interval.
Fig. 3. Kaplan–Meier survival curves of regional controls for combined evaluation of Tumor CD163+ macrophages and budding score. Patients were classified into three groups. Group 1 contained both low density of Tumor CD163+ macrophages and low grade of budding score, group 2 contained either high density of Tumor CD163+ macrophages or intermediate/high grade of budding score, and group 3 contained both high density of Tumor CD 163+ macrophages and intermediate/high grade of budding score. Twenty-two (35%), 22 (35%), and 18 (29%) patients were classified into groups 1, 2, and 3, respectively.

of previous studies evaluating patients in the early and advanced stages of OSCC or HNSCC. Although this topic has been widely examined, previous studies on the role of Tregs in prognosis revealed varying results, and the prognostic influence of Tregs remains unclear. This could be probably because of the changing relationship between the number of infiltrating Tregs and prognosis with tumor progression, as O'Higgins et al and Hanakawa et al described in their systematic reviews.

There are a few studies on CD45RO+ T cells in OSCC. One study showed that a high density of CD45RO+ T cells is significantly associated with a favorable prognosis. A meta-analysis of solid tumors, such as colorectal, esophageal, and gastric tumors, reported that tumor-infiltrating CD45RO+ T cells led to favorable clinical outcomes. Almost all studies included in the meta-analysis evaluated all stages of solid tumors. Turksma et al analyzed blood samples of patients with HNSCC. Although the percentage of effector memory T cells does not differ significantly across the four tumor stages, it is higher in patients with stage I and II tumors than in healthy donors, and subsequently declines in patients with advanced stages, displaying the highest prominence in stage II. Univariate analysis revealed a high infiltration of CD45RO+ T cells as a poor prognostic factor of RC. This may be consistent with the mechanism in which memory T cell differentiation tends to accelerate with tumor progression in early stages.

In early oral tongue SCC, it is assumed that when a tumor appears to be more aggressive, a protective immune response is derived, and TILs infiltration increases. These are activated owing to the elevated invasiveness of tumors; thus, the differentiation to memory T cells is accelerated. Finally, the immunosuppressive activity and high infiltration of Tregs are important in the prognosis of oral tongue SCC. The current study showed the status of each TIL subtype in the coexistence of both elimination and escape before and after microscopic metastases in early stages of oral tongue SCC. Although the prognostic significance of each subtype of TILs, such as CD4+ T cells, CD8+ T cells, Tregs, and memory T cells, may differ between the early and advanced stages, only M2 macrophages emerged as a consistent prognostic marker for all stages of the disease.

TB was a poor prognostic factor for both RC and DFS in univariate analysis and associated with poor RC in multivariate analysis, along with TILs. DOI was not a prognostic factor for RC or DFS in multivariate analysis. Moreover, the combination of TB and CD163 macrophages was suggested as a significant predictor of occult lymph node metastasis. Wang et al reported that the combination of invasion patterns and memory T cells is a prognostic marker for poor OS in early OSCC. Yu et al also reported that the iBD score, which evaluates inflammatory response and the BD model, is a risk factor for lymph node metastases and oral tongue SCC recurrence. Although TB and CD163 macrophages were poor prognostic factors according to multivariate analysis, there was no significant difference between groups 1 and 2. This was partly due to the patients with occult lymph metastases almost belonging to group 3. This result also suggested that the acquisition of epithelial–mesenchymal transition and activation of subtypes of TILs are associated with tumor progression and metastases. Therefore, elucidating the mechanism of epithelial–mesenchymal transition and immunoediting for tumor progression may demonstrate the usefulness of TB as not only a prognostic factor but also a determinant for the treatment strategy.

Nevertheless, a few limitations exist to this investigation. First, this study was not cohort-based, and involved relatively few patients, as only patients with early oral tongue SCC from one institution were enrolled. Given that the number of deaths was low, poor prognostic markers for survival could not be sufficiently evaluated. Second, the methods for evaluating subtypes of TILs are controversial. Shimizu et al evaluated the density of CD8+ T cells from five different anatomic locations and showed the prognostic difference across the locations. In this study, two areas, in which a larger number of each TIL subtype was found, were...
selected; the number of immune cells was counted using a computerized image analysis system. Thus, there may have been selection bias. Therefore, our results must be validated in a prospective cohort study of a large number of patients and reassessed by comparison with the advanced stages of oral tongue SCC.

**CONCLUSION**

Each TIL subtype may have different mechanisms and predictive significances for early and advanced stages of oral tongue SCC. The current study showed that CD163+ macrophages were poor prognostic markers of both RC and DFS, and the combination of TB and CD163+ macrophages was a novel prognostic marker for regional recurrences in early oral tongue SCC. Identification of TIL subtypes in daily clinical practice may lead to more successful and individualized therapeutic approaches for early oral tongue SCC.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the role of Sachie Osanai for her technical assistance with immunohistochemistry.

**AUTHOR CONTRIBUTIONS**

Conception and design of the study: Y.H., A.K., T.Y., N.O. Acquisition of data: Y.H., A.K., T.Y., M.F., T.M., N.K. Analysis and/or interpretation of data: Y.H., A.K., T.Y., N.O. Drafting the manuscript and revisiting the manuscript critically for important intellectual content: Y.H., A.K., T.Y., M.F., T.M., N.K., N.O. Approval of the version of the manuscript to be published: Y.H., A.K., T.Y., M.F., T.M., N.K., N.O. Agreement to be accountable for all aspects of the work: Y.H., A.K., T.Y., M.F., T.M., N.K., N.O.

**BIBLIOGRAPHY**

1. D’Cruz AK, Vaish R, Kapre N, et al. Ejective versus therapeutic necrosis in T2N0 tongue cancer. *J Oral Pathol Med* 2019;48:552–562.

2. Uyen AP, Wei WI, Wong YM, Tang KC. Ejective necrosis versus observation in the treatment of early oral tongue carcinoma. *Head Neck* 1997;19:583–588.

3. Lim YC, Lee JS, Koo BS, Kim SH, Kim YH, Choi EC. Treatment of contralateral NO neck in early squamous cell carcinoma of the oral tongue: ejective necrosis versus observation. *Laryngoscope* 2006;116:461–465.

4. Keeler N, Varatian JG, Pioto CA, Continho-Camilo CM, Kowalski LP. Does ejective necrosis in T1/T2 carcinoma of the oral tongue and floor of the mouth influence recurrence and survival rates? *Br J Oral Maxillofac Surg* 2014;52:590–597.

5. Brogle MA, Haerle SK, Huber GF, Haile SB, Stoeckli SJ. Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinoma: impact on survival. *Head Neck* 2013;35:600–605.

6. Huang SH, Hwang D, Lockwood G, Goldstein DP, O’Sullivan B. Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of published studies. *Cancer* 2009;114:1469–1476.

7. Ueno H, Murphy J, Jass JR, Mohchizuki H, Talbot IC. ‘Tumour budding’ as an index to estimate the potential of aggressiveness in rectal cancer. *Histopathology* 2002;40:127–132.

8. Karanmitopoulou E, Wartenberg M, Zebbe I, et al. Tumour budding in pancreateatic cancer revisited: validation of the ITBCC scoring system. *Histopathology* 2018;73:137–146.

9. Hori Y, Kubota A, Yokose T, et al. Predictive significance of tumor depth and budding for late lymph node metastases in patients with clinical N0 early oral tongue carcinoma. *Head Neck Pathol* 2017;11:477–486.

10. Hori Y, Kubota A, Yokose T, Furukawa M, Matsuhashita T, Orisada N. Association between pathological invasion patterns and late lymph node metastases in patients with surgically treated clinical no early oral tongue carcinoma. *Head Neck* 2019;42:238–243.

11. Almangush A, Bello IO, Keski-Santti H, et al. Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early-stage oral tongue cancer. *Head Neck* 2014;36:681–689.

12. Shimizu S, Miyazaki A, Sonoda T, et al. Tumour budding is an independent prognostic marker in early stage oral squamous cell carcinoma: with special reference to the mode of invasion and worst pattern of invasion. *PLoS One* 2018;13:e0195451.

13. Xie N, Wang C, Liu X, et al. Tumor budding correlates with occult cervical lymph node metastasis and poor prognosis in clinical early-stage squamous cell carcinoma. *J Oral Pathol Med* 2015;44:266–272.

14. Zhu Y, Liu H, Xie N, et al. Impact of tumor budding in head and neck squamous cell carcinoma: a meta-analysis. *Head Neck* 2019;41:542–550.

15. He H, Wu T, Wu TY, Cheng HR, Yang CC, Wu CH. Significance of tumor budding in oral cancer survival and its relevance to the eighth edition of the American Joint Committee on Cancer staging system. *Head Neck* 2019;41:2991–3001.

16. Teng MW, Ngio SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. *Cancer Res* 2015;75:2319–2415.

17. Wang S, Xu J, Meng Y, et al. In situ memory T cells and patterns of invasion predict outcome in patients with early-stage oral squamous cell carcinoma. *Cancer Biomark* 2017;19:199–205.

18. Yu P, Wang W, Zhuang Z, et al. A novel prognostic model for tongue squamous cell carcinoma based on the characteristics of tumour and its microenvironment: iBD score. *Histopathology* 2019;74:766–769.

19. Alves AM, Diel LF, Lamers ML. Macrophages and prognosis of oral squamous cell carcinoma: a systematic review. *J Oral Pathol Med* 2018;47:460–467.

20. Shimizu S, Hiratake H, Kikue K, et al. Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma. *Cancer Med* 2019;8:80–93.

21. Stogowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M. Immunohistochemical analysis of Foxp3(+), CD4(+), CD8(+) T cells infiltrates and PD-L1 in oral squamous carcinoma. *Pathol Oncol Res* 2018;24:497–505.

22. Mandal R, Senhabougou Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. *J Oncol* 2016;1:e98829.

23. Boxberg M, Leising L, Steiger K, et al. Conception and clinical impact of the immunologic tumor microenvironment in oral squamous cell carci-

24. Ali HB, Provenzano E, Dawson SJ, et al. Association between CD4+ T-cell infiltration and breast cancer survival in 12,439 patients. *Ann Oncol* 2014;25:1536–1543.

25. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. *J Clin Oncol* 2011;29:610–618.

26. Whiteside TL. Regulatory T cell subsets in human cancer: are they regulat-

27. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M. Immunohistopa-

28. 2017;43:521.

29. Sullivan B. Predictive value of tumour thickness for cervical lymph-node involvement in squamous cell carcinoma based on the characteristics of tumour and its micro-

30. Karamitopoulou E, Wartenberg M, Zebbe I, et al. Tumour budding in pancreateatic cancer revisited: validation of the ITBCC scoring system. *Histopa-

31. Hanakawa H, Orita Y, Sato Y, et al. Regulatory T-cell infiltration in tongue squamous cell carcinoma. Acta Oncologica 2013;52:459–464.

32. Fang J, Li X, Ma D, et al. Prognostic significance of CD8+ and CD163+ tumor associated macrophages in head and neck squamous cell carcinoma: a systematic review and meta-analysis. *Oral Oncol* 2019;93:66–75.

33. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. *J Clin Oncol* 2009;27:5944–5952.

34. Huang Z, Xie N, Liu H, et al. The prognostic role of tumor-infiltrating lym-

35. 2010;37:386–393.

36. 2002;8:442.

37. 2018;74:766–769.

38. 2019;8:442.

39. 2018;77:536–540.

40. 2018;11:345–363.

41. 2011;1277–1322.

42. 2014;9:744–752.

43. 2019;19:577–584.

44. 2019;18:340–356.

45. 2015;37:1149–1156.

46. 2018;6:386–403.

47. 2013;11:477–486.

48. 2019;11:477–486.

49. 2018;17:375.

50. 2010;30:666–672.

51. 2010;109:744–752.

52. 2017;11:345–363.

53. 2010;109:744–752.

54. 2017;11:345–363.

55. 2017;11:345–363.

56. 2017;11:345–363.

57. 2017;11:345–363.

58. 2017;11:345–363.